Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

1,846 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Expression of DNA ligase IV is linked to poor prognosis and characterizes a subset of prostate cancers harboring TMPRSS2:ERG fusion and PTEN deletion.
Grupp K, Roettger L, Kluth M, Hube-Magg C, Simon R, Lebok P, Minner S, Tsourlakis MC, Koop C, Graefen M, Adam M, Haese A, Wittmer C, Sauter G, Wilczak W, Huland H, Schlomm T, Steurer S, Krech T. Grupp K, et al. Among authors: adam m. Oncol Rep. 2015 Sep;34(3):1211-20. doi: 10.3892/or.2015.4080. Epub 2015 Jun 25. Oncol Rep. 2015. PMID: 26134445
Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion-positive prostate cancers.
Krohn A, Seidel A, Burkhardt L, Bachmann F, Mader M, Grupp K, Eichenauer T, Becker A, Adam M, Graefen M, Huland H, Kurtz S, Steurer S, Tsourlakis MC, Minner S, Michl U, Schlomm T, Sauter G, Simon R, Sirma H. Krohn A, et al. Among authors: adam m. J Pathol. 2013 Sep;231(1):130-41. doi: 10.1002/path.4223. J Pathol. 2013. PMID: 23794398
High mitochondria content is associated with prostate cancer disease progression.
Grupp K, Jedrzejewska K, Tsourlakis MC, Koop C, Wilczak W, Adam M, Quaas A, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Schlomm T, Minner S, Steurer S. Grupp K, et al. Among authors: adam m. Mol Cancer. 2013 Nov 21;12(1):145. doi: 10.1186/1476-4598-12-145. Mol Cancer. 2013. PMID: 24261794 Free PMC article.
The prognostic impact of high Nijmegen breakage syndrome (NBS1) gene expression in ERG-negative prostate cancers lacking PTEN deletion is driven by KPNA2 expression.
Grupp K, Boumesli R, Tsourlakis MC, Koop C, Wilczak W, Adam M, Sauter G, Simon R, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A. Grupp K, et al. Among authors: adam m. Int J Cancer. 2014 Sep 15;135(6):1399-407. doi: 10.1002/ijc.28778. Epub 2014 Feb 26. Int J Cancer. 2014. PMID: 24510842
NY-ESO-1 expression is tightly linked to TMPRSS2-ERG fusion in prostate cancer.
Grupp K, Ospina-Klinck D, Tsourlakis MC, Koop C, Wilczak W, Adam M, Simon R, Sauter G, Izbicki JR, Graefen M, Huland H, Steurer S, Schlomm T, Minner S, Quaas A. Grupp K, et al. Among authors: adam m. Prostate. 2014 Jul;74(10):1012-22. doi: 10.1002/pros.22816. Epub 2014 May 1. Prostate. 2014. PMID: 24789172
TMPRSS2-ERG fusions are strongly linked to young patient age in low-grade prostate cancer.
Steurer S, Mayer PS, Adam M, Krohn A, Koop C, Ospina-Klinck D, Tehrani AA, Simon R, Tennstedt P, Graefen M, Wittmer C, Brors B, Plass C, Korbel J, Weischenfeldt J, Sauter G, Huland H, Tsourlakis MC, Minner S, Schlomm T. Steurer S, et al. Among authors: adam m. Eur Urol. 2014 Dec;66(6):978-81. doi: 10.1016/j.eururo.2014.06.027. Epub 2014 Jul 9. Eur Urol. 2014. PMID: 25015038
Saccharomyces cerevisiae-like 1 overexpression is frequent in prostate cancer and has markedly different effects in Ets-related gene fusion-positive and fusion-negative cancers.
Burdelski C, Barreau Y, Simon R, Hube-Magg C, Minner S, Koop C, Graefen M, Heinzer H, Sauter G, Wittmer C, Steurer S, Adam M, Huland H, Schlomm T, Tsourlakis MC, Quaas A. Burdelski C, et al. Among authors: adam m. Hum Pathol. 2015 Apr;46(4):514-23. doi: 10.1016/j.humpath.2014.06.006. Epub 2014 Jun 26. Hum Pathol. 2015. PMID: 25701228
HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.
Zabalza CV, Adam M, Burdelski C, Wilczak W, Wittmer C, Kraft S, Krech T, Steurer S, Koop C, Hube-Magg C, Graefen M, Heinzer H, Minner S, Simon R, Sauter G, Schlomm T, Tsourlakis MC. Zabalza CV, et al. Among authors: adam m. Oncotarget. 2015 May 20;6(14):12822-34. doi: 10.18632/oncotarget.3431. Oncotarget. 2015. PMID: 25825985 Free PMC article.
1,846 results